Blood VEGF level-lowering agent containing IL-6 antagonist as the active ingredient

• US 8,173,126 B2
• Filed: 06/18/2007
• Issued: 05/08/2012
• Est. Priority Date: 10/27/2000
• Status: Expired due to Term

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Inventors: Yoshizaki, Kazuyuki, Nishimoto, Norihiro
• Primary Examiner(s): Bunner, Bridget E
• Assistant Examiner(s): HAMUD, FOZIA M
• Application Number:
  US11/812,296
• Publication Number:
  US 20070243189A1
• Time in Patent Office: 1,786 Days
• Field of Search: None
• US Class Current: 424/133.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons

Abstract

A blood vascular endothelial growth factor (VEGF) level-lowering agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

Claims

1. A method for lowering blood VEGF level, comprising measuring a serum level of VEGF and administering to a patient having Multicentric Castleman'"'"'s Disease (MCD) and in need of lowering blood VEGF level an antibody against IL-6 receptor in an amount effective to lower blood VEGF level.

2. The method according to claim 1, wherein the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.

3. The method according to claim 1, in which the antibody against IL-6 receptor is a recombinant antibody.

4. The method according to claim 1, in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor.

5. The method of claim 1, wherein the blood VEGF level is lowered to at least 500 pg/ml.

6. A method for lowering blood VEGF level, comprising measuring a serum level of VEGF and administering to a patient having Multicentric Castleman'"'"'s Disease (MCD) and in need of lowering blood VEGF level an antibody against IL-6 receptor in an amount effective to lower blood VEGF level, in which the antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

7. The method according to claim 6, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody.

8. A method for lowering blood VEGF level, comprising measuring a serum level of VEGF and administering to a patient having Multicentric Castleman'"'"'s Disease (MCD) and in need of lowering blood VEGF level an antibody against IL-6 receptor in an amount effective to lower blood VEGF level, in which the antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

9. The method according to claim 8, in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

10. A method for lowering blood VEGF level, comprising measuring a serum level of VEGF and administering to a patient having Multicentric Castleman'"'"'s Disease (MCD) and in need of lowering blood VEGF level an antibody against IL-6 receptor in an amount effective to lower blood VEGF level, in which the antibody against IL-6 receptor is a humanized PM-1 antibody.

11. A method for inhibiting angiogenesis, comprising measuring a serum level of VEGF and administering to a patient having Multicentric Castleman'"'"'s Disease (MCD) and in need of lowering blood VEGF level an antibody against IL-6 receptor in an amount effective to inhibit angiogenesis.

12. The method according to claim 11, in which the antibody against IL-6 receptor is a monoclonal antibody against IL-6 receptor.

13. The method according to claim 12, in which the monoclonal antibody against IL-6 receptor is a monoclonal antibody against human IL-6 receptor.

14. The method according to claim 13, in which the monoclonal antibody against human IL-6 receptor is PM-1 antibody.

15. The method according to claim 12, in which the monoclonal antibody against IL-6 receptor is a monoclonal antibody against mouse IL-6 receptor.

16. The method according to claim 15, in which the monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

17. The method according to claim 11, in which the antibody against IL-6 receptor is a recombinant antibody.

18. The method according to claim 11, in which the antibody against IL-6 receptor is a chimeric antibody or a humanized antibody against IL-6 receptor.

19. The method according to claim 18, in which the humanized antibody against IL-6 receptor is a humanized PM-1 antibody.